A multinational pharmaceutical company is seeking novel oral drug molecules for immunology and inflammation diseases. The modalities include oral small molecules, protein or RNA degraders, oral peptides, etc. Specifically, our client is most interested in novel oral therapeutics that act on clinically validated targets with biologic drugs in Phase 1 and beyond.
Approaches of Interest:
- All immunology and inflammation diseases are of interest. Therapeutics that treat asthma, COPD, IPF and IBD are of highest priority
- Modalities of interest include small molecules...